Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study

In this study (n=2216), once-daily fixed combination of mometasone furoate (MF) plus indacaterol acetate (MF-IND) improved lung function versus MF monotherapy and high-dose MF-IND was non-inferior to twice-daily high-dose fluticasone–salmeterol for improvement in trough FEV1.

SPS commentary:

A related commentary notes that this study demonstrates the efficacy and safety of the novel once-daily mometasone furoate-indacaterol acetate fixed dose combination inhaler, expanding the spectrum of once-daily inhaled corticosteroid-long-acting beta agonist inhalers and may improve outcomes by simplifying regimens and improving adherence.


This new combination inhaler (Bemrist; available in various strengths) was approved in the EU in June 2020 for the maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.


The Lancet Respiratory Medicine

Resource links: